NICE has increased its capacity for appraising new drugs and treatments, and will be able to review existing NICE apprai

  • PDF / 136,261 Bytes
  • 1 Pages / 623.591 x 841.847 pts Page_size
  • 93 Downloads / 206 Views

DOWNLOAD

REPORT

1173-5503/10/0592-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

PharmacoEconomics & Outcomes News 28 Nov 2009 No. 592

1

Data Loading...

Recommend Documents
HAS to be NICE?

174 28 114KB

Nice Numbers

192 57 12MB

Decisions by ICER and NICE discordant for some cancer drugs

144 41 167KB

NICE evaluations of drugs, medical devices and diagnostics

167 48 164KB

Have a nice day!

144 88 2MB

UK NICE has succeeded in reducing variation in patient care,

155 85 131KB

NICE recommends apixiban and ranibizumab . . .

165 13 112KB

A Nice Retirement?

198 6 4MB

National Institute for Health and Care Excellence (NICE)

174 66 23MB

NICE starts review of nusinersen Managed Access Agreement

146 35 163KB

Court to rule on transparency of NICE

187 23 120KB

NICE recommends isatuximab with pomalidomide and dexamethasone

151 71 163KB